Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde

被引:164
作者
Anderson, VE
Osheroff, N
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA
关键词
D O I
10.2174/1381612013398013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quinolones are a very important family of antibacterial agents that are widely prescribed for the treatment of infections in humans. Although the founding members of this drug class had little clinical impact, successive generations include the most active and broad spectrum oral antibacterials currently in use. In contrast to most other anti-infective drugs, quinolones do not kill bacteria by inhibiting a critical cellular process. Rather, they corrupt the activities of two essential enzymes, DNA gyrase and topoisomerase IV, and induce them to kill cells by generating high levels of double-stranded DNA breaks. A second unique aspect of quinolones is their differential ability to target these two enzymes in different bacteria. Depending upon the bacterial species and quinolone employed, either DNA gyrase or topoisomerase IV serves as the primary cytotoxic target of drug action. While this unusual feature initially stymied development of quinolones with high activity against Gram-positive bacteria, it ultimately opened new vistas for the clinical use of this drug class. In addition to the antibacterial quinolones, specific members of this drug family display high activity against eukaryotic type II topoisomerases, as well as cultured mammalian cells and in vivo tumor models. These antineoplastic quinolones represent a potentially important source of new anticancer agents and provide an opportunity to examine drug mechanism across divergent species. Because of the clinical importance of quinolones, this review will discuss the mechanistic basis for drug efficacy and interactions between these compounds and their topoisomerase targets.
引用
收藏
页码:337 / 353
页数:17
相关论文
共 150 条
  • [1] ACKERMAN P, 1988, J BIOL CHEM, V263, P12653
  • [2] THE ROLE OF TOPOISOMERASE-IV IN PARTITIONING BACTERIAL REPLICONS AND THE STRUCTURE OF CATENATED INTERMEDIATES IN DNA-REPLICATION
    ADAMS, DE
    SHEKHTMAN, EM
    ZECHIEDRICH, EL
    SCHMID, MB
    COZZARELLI, NR
    [J]. CELL, 1992, 71 (02) : 277 - 288
  • [3] Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV -: Changes in drug mechanism across evolutionary boundaries
    Anderson, VE
    Zaniewski, RP
    Kaczmarek, FS
    Gootz, TD
    Osheroff, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (50) : 35927 - 35932
  • [4] Topoisomerase IV catalysis and the mechanism of quinolone action
    Anderson, VE
    Gootz, TD
    Osheroff, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) : 17879 - 17885
  • [5] ANDERSON VE, 1999, IN PRESS BIOCHEMISTR
  • [6] The future of the quinolones
    Andriole, VT
    [J]. DRUGS, 1999, 58 (Suppl 2) : 1 - 5
  • [7] NOVEL HELA TOPOISOMERASE-II IS THE II-BETA ISOFORM - COMPLETE CODING SEQUENCE AND HOMOLOGY WITH OTHER TYPE-II TOPOISOMERASES
    AUSTIN, CA
    SNG, JH
    PATEL, S
    FISHER, LM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1172 (03) : 283 - 291
  • [8] Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO
  • [9] 2-Q
  • [10] USE OF INVITRO TOPOISOMERASE-II ASSAYS FOR STUDYING QUINOLONE ANTIBACTERIAL AGENTS
    BARRETT, JF
    GOOTZ, TD
    MCGUIRK, PR
    FARRELL, CA
    SOKOLOWSKI, SA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) : 1697 - 1703